Recon: Boston Scientific to purchase Penumbra for $14.5B; FDA delays reviews of two drugs in Commissioner’s voucher program
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsProduct LifecycleUnited States